HER-TEMPO - Real world treatment-related outcomes on T-DXd in Canada

Trial Identifier:	D9673R00032
Sponsor:	AstraZeneca
Collaborator:	Daiichi Sankyo
NCTID::	NCT06386263
Start Date:	April 2024
Primary Completion Date:	April 2025
Study Completion Date:	April 2025
Condition:	Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Canada, Ontario	Oakville, Ontario, Canada, L6H1A7

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.